Technical Analysis for EVG - Evgen Pharma Plc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Flat |
Historical EVG trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Inside Day | Range Contraction | 0.00% | |
50 DMA Resistance | Bearish | 0.00% | |
Crossed Above 20 DMA | Bullish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
20 DMA Resistance | Bearish | 3.16% | |
Doji - Bullish? | Reversal | 3.16% | |
Fell Below 20 DMA | Bearish | 3.16% | |
Inside Day | Range Contraction | 3.16% | |
Down 3 Days in a Row | Weakness | 3.16% | |
20 DMA Support | Bullish | 0.62% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Possible NR7 | about 20 hours ago |
Possible Inside Day | about 20 hours ago |
10 DMA Resistance | about 20 hours ago |
Possible Pocket Pivot | about 22 hours ago |
10 DMA Support | about 22 hours ago |
Get a Trading Assistant
Evgen Pharma Plc Description
Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Chemistry Pharmaceutical Medicine Pipe Clinic Disease Cancer Therapy Rtt Drug Development Tumor Pharmaceutical Products Scs Breast Cancer Intensive Care Medicine Stem Cells Asos Multiple Sclerosis Neurosurgery Organic Chemistry Prostate Cancer Tumors
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 17.0 |
52 Week Low | 3.0 |
Average Volume | 1,261,585 |
200-Day Moving Average | 10.37 |
50-Day Moving Average | 8.40 |
20-Day Moving Average | 7.99 |
10-Day Moving Average | 8.19 |
Average True Range | 0.40 |
ADX | 18.96 |
+DI | 27.76 |
-DI | 21.11 |
Chandelier Exit (Long, 3 ATRs ) | 8.02 |
Chandelier Exit (Short, 3 ATRs ) | 8.29 |
Upper Bollinger Band | 8.75 |
Lower Bollinger Band | 7.24 |
Percent B (%b) | 0.6 |
BandWidth | 18.83 |
MACD Line | -0.05 |
MACD Signal Line | -0.09 |
MACD Histogram | 0.0366 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 8.60 | ||||
Resistance 3 (R3) | 8.60 | 8.45 | 8.53 | ||
Resistance 2 (R2) | 8.45 | 8.34 | 8.45 | 8.50 | |
Resistance 1 (R1) | 8.30 | 8.26 | 8.23 | 8.30 | 8.47 |
Pivot Point | 8.15 | 8.15 | 8.11 | 8.15 | 8.15 |
Support 1 (S1) | 8.00 | 8.04 | 7.93 | 8.00 | 7.83 |
Support 2 (S2) | 7.85 | 7.96 | 7.85 | 7.80 | |
Support 3 (S3) | 7.70 | 7.85 | 7.78 | ||
Support 4 (S4) | 7.70 |